Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JANSSEN SUFFENTA ANALGESIC/ANESTHETIC DISTRIBUTION WILL BEGIN IN MID-JUNE

Executive Summary

JANSSEN SUFFENTA ANALGESIC/ANESTHETIC DISTRIBUTION WILL BEGIN IN MID-JUNE, the firm announced following FDA approval of the drug on May 4. Sufenta's (sufentanil citrate) price to whslrs. will be: $41.70 for 1 ml ampules, boxes of 10; $72.50 for 2 ml ampules, boxes of 10; and $136.80 for 5 ml ampules, boxes of 10. The product's labeling states that Sufenta is indicated for use as "an analgesic adjunct . . . in the maintenance of balanced general anesthesia." It is also indicated for use as "a primary anesthetic for the induction and maintenance of anesthesia with 100% oxygen in patients undergoing major surgical procedures such as cardiovascular surgery, neurosurgical procedures in the sitting position to provide favorable myocardial and cerebral oxygen balance or when extended post-operative ventilation is anticipated." A May 7 Janssen press release asserts that Sufenta "provides smoother, more rapid induction; smoother, more stable intraoperative course; superior hemodynamic stability; more effective blocking of surgical stress responses; and faster, more comfortable patient recovery as compared to presently available anesthetic agents." According to the release, the product "has five to seven times more analgesic potency than fentanyl," marketed by the J&J subsidiary under the brandname Sublimaze, and "625 times greater analgesic potency than morphine." In addition, the company stated that "when Sufenta is used as the primary anesthetic agent in open-heart surgery, patients anesthetized with the new agent showed a markedly reduced need for vasoactive agents compared with patients anesthetized with fentanyl or morphine." Sufenta is one of two new analgesic/anesthetic drugs developed by Janssen. A second, Alfenta, (alfentanil HCl) is currently in Phase III clinical trials. Another anesthetic developed by the company in recent years, etomidate, is licensed in the U.S. by Abbott and marketed under the brandname Amidate. The original NDA for Sufenta was filed by Janssen June 17, 1983.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006565

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel